Facing clinical failures and pipeline attrition, ADC Therapeutics announced a 30% workforce reduction, a U.K. research site closure, and discontinuation of some preclinical solid tumor programs. The restructuring reallocates resources to prioritized oncology assets but underscores the challenges biopharma firms face amid competitive landscapes and clinical setbacks.